ARCT
Price
$12.00
Change
-$0.21 (-1.72%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
324.9M
4 days until earnings call
BNTX
Price
$111.27
Change
-$0.03 (-0.03%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
26.77B
87 days until earnings call
Interact to see
Advertisement

ARCT vs BNTX

Header iconARCT vs BNTX Comparison
Open Charts ARCT vs BNTXBanner chart's image
Arcturus Therapeutics Holdings
Price$12.00
Change-$0.21 (-1.72%)
Volume$3.93K
Capitalization324.9M
BioNTech SE American Depositary Share
Price$111.27
Change-$0.03 (-0.03%)
Volume$6.04K
Capitalization26.77B
ARCT vs BNTX Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BNTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. BNTX commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and BNTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (ARCT: $12.21 vs. BNTX: $111.35)
Brand notoriety: ARCT and BNTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 92% vs. BNTX: 113%
Market capitalization -- ARCT: $324.9M vs. BNTX: $26.77B
ARCT [@Biotechnology] is valued at $324.9M. BNTX’s [@Biotechnology] market capitalization is $26.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileBNTX’s FA Score has 2 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • BNTX’s FA Score: 2 green, 3 red.
According to our system of comparison, BNTX is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 3 TA indicator(s) are bullish while BNTX’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 3 bullish, 6 bearish.
  • BNTX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BNTX is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а -3.63% price change this week, while BNTX (@Biotechnology) price change was +3.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.15%. For the same industry, the average monthly price growth was +8.44%, and the average quarterly price growth was +12.41%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

BNTX is expected to report earnings on Nov 03, 2025.

Industries' Descriptions

@Biotechnology (+1.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BNTX($26.8B) has a higher market cap than ARCT($325M). BNTX YTD gains are higher at: -2.282 vs. ARCT (-28.049). ARCT has higher annual earnings (EBITDA): -63.92M vs. BNTX (-447M). BNTX has more cash in the bank: 14.1B vs. ARCT (217M). ARCT has less debt than BNTX: ARCT (42.7M) vs BNTX (293M). BNTX has higher revenues than ARCT: BNTX (2.75B) vs ARCT (131M).
ARCTBNTXARCT / BNTX
Capitalization325M26.8B1%
EBITDA-63.92M-447M14%
Gain YTD-28.049-2.2821,229%
P/E RatioN/A161.76-
Revenue131M2.75B5%
Total Cash217M14.1B2%
Total Debt42.7M293M15%
FUNDAMENTALS RATINGS
ARCT vs BNTX: Fundamental Ratings
ARCT
BNTX
OUTLOOK RATING
1..100
6063
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
2
Undervalued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9692
PRICE GROWTH RATING
1..100
6447
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
4650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BNTX's Valuation (2) in the null industry is somewhat better than the same rating for ARCT (43) in the Pharmaceuticals Major industry. This means that BNTX’s stock grew somewhat faster than ARCT’s over the last 12 months.

BNTX's Profit vs Risk Rating (88) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that BNTX’s stock grew similarly to ARCT’s over the last 12 months.

BNTX's SMR Rating (92) in the null industry is in the same range as ARCT (96) in the Pharmaceuticals Major industry. This means that BNTX’s stock grew similarly to ARCT’s over the last 12 months.

BNTX's Price Growth Rating (47) in the null industry is in the same range as ARCT (64) in the Pharmaceuticals Major industry. This means that BNTX’s stock grew similarly to ARCT’s over the last 12 months.

BNTX's P/E Growth Rating (1) in the null industry is significantly better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that BNTX’s stock grew significantly faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTBNTX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 16 days ago
81%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BNTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SRCRF0.170.02
+11.26%
Scorpio Gold Corp.
MINBY17.200.96
+5.94%
Minebea Mitsumi Inc.
TSMRF23.74N/A
N/A
Tsumura & Co
ILIKF0.54-0.01
-1.26%
Ilika PLC.
BAYZF29.20-2.66
-8.35%
Bayer A.G.

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with RXRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+3.21%
RXRX - ARCT
51%
Loosely correlated
-0.90%
MRNA - ARCT
51%
Loosely correlated
-2.77%
RGNX - ARCT
51%
Loosely correlated
-0.72%
BEAM - ARCT
51%
Loosely correlated
-2.14%
PDSB - ARCT
50%
Loosely correlated
-1.77%
More